Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Intestinal Obstruction I: Introduction01:29

Intestinal Obstruction I: Introduction

Intestinal obstruction is a partial or complete blockage of the small or large intestine that disrupts the normal flow of intestinal contents through the lumen. This interruption impairs digestion, absorption, and fluid balance, and may lead to serious complications if not treated promptly.Mechanical ObstructionMechanical obstruction occurs when a physical blockage prevents intestinal contents from passing, arising from within the lumen or the bowel wall, or from external compression.Adhesions,...
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal of hematology & oncology·2026
Same author

Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review.

Expert review of hematology·2026
Same author

Pediatric blastic plasmacytoid dendritic cell neoplasms are molecularly defined by recurrent <i>MYB</i> rearrangements: clinical and molecular insights.

Haematologica·2026
Same author

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Cancer·2026
Same author

Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.

Blood advances·2026
Same author

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

American journal of hematology·2026

Related Experiment Video

Updated: Jul 5, 2026

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

Solifenacin-induced small bowel pseudo-obstruction.

Naveen Pemmaraju1, Leonard S Feldman

  • 1Department of General Internal Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA.

Journal of Hospital Medicine
|April 29, 2008
PubMed
Summary

Solifenacin, a medication for bladder overactivity, can cause small bowel pseudo-obstruction. This case report details a patient

Area of Science:

  • Geriatric Medicine
  • Gastroenterology
  • Pharmacology

Background:

  • Urinary retention and small bowel obstruction are significant clinical concerns in elderly patients.
  • Solifenacin is commonly prescribed for overactive bladder.
  • Medication side effects can mimic serious gastrointestinal pathology.

Observation:

  • An 89-year-old female presented with symptoms of small bowel obstruction and urinary retention.
  • The patient had recently been initiated on solifenacin for bladder overactivity.
  • Clinical presentation suggested a possible medication-induced adverse event.

Findings:

  • Discontinuation of solifenacin led to complete resolution of the patient's gastrointestinal and urinary symptoms.
  • The patient remained symptom-free for over six months post-cessation without surgical intervention.

Related Experiment Videos

Last Updated: Jul 5, 2026

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

  • This represents the first documented case of solifenacin-induced small bowel pseudo-obstruction.

    • Implications:

    • Clinicians should consider solifenacin as a potential cause of small bowel pseudo-obstruction in patients presenting with relevant symptoms.
    • Early recognition and withdrawal of the offending agent can prevent the need for invasive procedures.
    • This finding highlights the importance of thorough medication review in geriatric patients with unexplained gastrointestinal issues.